Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks Treatment

  1. Christofides, E.A.
  2. Stankiewicz, A.
  3. Denham, D.
  4. Bellido, D.
  5. Franek, E.
  6. Nakhle, S.
  7. Łukaszewicz, M.
  8. Reed, J.
  9. Cózar-León, V.
  10. Kosch, C.
  11. Karaś, P.
  12. Fitz-Patrick, D.
  13. Handelsman, Y.
  14. Warren, M.
  15. Hollander, P.
  16. Huffman, D.
  17. Raskin, P.
  18. Oroszlán, T.
  19. Lillestol, M.
  20. Ovalle, F.
Journal:
Endocrine Practice

ISSN: 1934-2403 1530-891X

Year of publication: 2024

Volume: 30

Issue: 9

Pages: 810-816

Type: Article

DOI: 10.1016/J.EPRAC.2024.06.002 GOOGLE SCHOLAR